Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 24

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 24
---
 under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                    
 securities purchased by L1 Capital Global Opportunities Master Fund in the March PIPE Financing: (i) 435,454 shares of common stock; (ii) 4,110,000 shares of common stock issuable upon the exercise of          
 Pre-Funded Warrants; (iii) 45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 204,545,430 shares of common stock issuable upon the exercise of Series B     
 Common Stock Warrants. The Pre-Funded Warrants and Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of  
 the Pre-Funded Warrants and Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address 
 for L1 Capital Global Opportunities Master Fund is 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman KY1-1001, Cayman Islands.                                                                     |

| (14) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
 securities purchased by S.H.N Financial Investments Ltd. in the March PIPE Financing: (i) 885,454 shares of common stock; (ii) 3,660,000 shares of common stock issuable upon the exercise of Pre-Funded                                                                                                                                                                                                                                                                                                                                                                                                                                        
 Warrants; (iii) 45,454,540 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iv) 204,545,430 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Pre-Funded Warrants and Common Warrants are subject to a beneficial ownership limitation of 9.99%, which limitation restricts the selling stockholder from exercising that portion of the Pre-Funded Warrants and Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address for S.H.N 
 Financial Investments Ltd. is Arik Einstein 3, Herzliya, Israel.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

12

PLAN OF DISTRIBUTION The selling stockholders, which as used in this prospectus includes the selling stockholders listed in the section